A longitudinal study of risk factors for community-based home help services in Alzheimer’s disease: the influence of cholinesterase inhibitor therapy

A longitudinal study of risk factors for community-based home help services in Alzheimer’s disease: the influence of cholinesterase inhibitor therapy

Carina Wattmo, Elisabeth Paulsson, Lennart Minthon, Elisabet LondosClinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Malmö, SwedenBackground: To investigate the long-term effects of cholinesterase inhibitor (ChEI) therapy and the influence of s...

Full description

Bibliographic Details
Main Authors:	Wattmo C, Paulsson E, Minthon L, Londos E
Format:	Article
Language:	English
Published:	Dove Medical Press 2013-03-01
Series:	Clinical Interventions in Aging
Subjects:	Alzheimer's disease Cholinesterase inhibitors Home help services Gender Longitudinal study Predictors
Online Access:	https://www.dovepress.com/nbspa-longitudinal-study-of-risk-factors-for-community-based-home-help-peer-reviewed-article-CIA

Similar Items

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
by: Wattmo Carina, et al.
Published: (2012-11-01)

Solitary living in Alzheimer’s disease over 3 years: association between cognitive and functional impairment and community-based services
by: Wattmo C, et al.
Published: (2014-11-01)

Early- versus late-onset Alzheimer’s disease in clinical practice: cognitive and global outcomes over 3 years
by: Carina Wattmo, et al.
Published: (2017-08-01)

CHOLINESTERASE INHIBITORS IN THE TREATMENT OF DEMENTIA ALZHEIMER’S
by: Prameidya Primaniar S
Published: (2013-03-01)

Early- versus Late-Onset Alzheimer Disease: Long-Term Functional Outcomes, Nursing Home Placement, and Risk Factors for Rate of Progression
by: Carina Wattmo, et al.
Published: (2017-05-01)

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis
by: Noll Campbell, et al.
Published: (2008-12-01)

Reassessment of the dementia diagnosis of Alzheimer's disease in patients enrolled on the cholinesterase inhibitors dispensation program
by: Magda Cristina Flaitt Sanches Piovesana, et al.

Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease
by: Hafsa Amat-ur-Rasool, et al.
Published: (2021-02-01)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
by: Ben Seltzer
Published: (2009-12-01)

Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients
by: Martina Zimmermann, et al.
Published: (2005-06-01)

Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story
by: Lam Benjamin, et al.
Published: (2009-12-01)

Serum Concentrations of Cholinesterase Inhibitors in Patients With Alzheimer’s Dementia Are Frequently Below the Recommended Levels
by: Marion Ortner, et al.
Published: (2020-05-01)

Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials
by: Kai-Xin Dou, et al.
Published: (2018-12-01)

Trends and disparities in the use of cholinesterase inhibitors to treat Alzheimer’s disease dispensed by the Brazilian public health system – 2008 to 2014: a nation-wide analysis
by: Flávia Silva de Moraes, et al.

Use of Medications for Management of Alzheimer’s Disease in Ontario’s Home Care Population
by: Jantzi, Micaela
Published: (2010)

Use of Medications for Management of Alzheimer’s Disease in Ontario’s Home Care Population
by: Jantzi, Micaela
Published: (2010)

Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer’s Disease and Other Dementias
by: Taim Muayqil, et al.
Published: (2012-11-01)

QuinoxalineTacrine QT78, a Cholinesterase Inhibitor as a Potential Ligand for Alzheimer’s Disease Therapy
by: Eva Ramos, et al.
Published: (2019-04-01)

Good rate of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease after three months of treatment: An open-label study
by: Luis Felipe José Ravic de Miranda, et al.

Bis (diamines) Cu and Zn Complexes of Flurbiprofen as Potential Cholinesterase Inhibitors: In Vitro Studies and Docking Simulations
by: Muhammad Jamil, et al.
Published: (2021-02-01)

Comparative Kinetics of Acetyl- and Butyryl-Cholinesterase Inhibition by Green Tea Catechins|Relevance to the Symptomatic Treatment of Alzheimer’s Disease
by: Edward J. Okello, et al.
Published: (2020-04-01)

Synthesis and Biological Evaluation of Benzochromenopyrimidinones as Cholinesterase Inhibitors and Potent Antioxidant, Non-Hepatotoxic Agents for Alzheimer’s Disease
by: Youssef Dgachi, et al.
Published: (2016-05-01)

In vitro antioxidant and cholinesterase inhibitory activities of Elatostema papillosum leaves and correlation with their phytochemical profiles: a study relevant to the treatment of Alzheimer’s disease
by: A. S. M. Ali Reza, et al.
Published: (2018-04-01)

Synthesis, pharmacology and molecular docking on multifunctional tacrine-ferulic acid hybrids as cholinesterase inhibitors against Alzheimer’s disease
by: Jie Zhu, et al.
Published: (2018-01-01)

Non-Alkaloid Cholinesterase Inhibitory Compounds from Natural Sources
by: Alfred Ngenge Tamfu, et al.
Published: (2021-09-01)

An In Vitro and In Vivo Cholinesterase Inhibitory Activity of Pistacia khinjuk and Allium sativum Essential Oils
by: Peyman Ghajarbeygi, et al.
Published: (2019-12-01)

Assessing the Safety of Cholinesterase Inhibitor Discontinuation in Patients with Moderate to Severe Alzheimer’s Disease in a Long Term Care Setting
by: O'Regan, Jordana
Published: (2014)

Assessing the Safety of Cholinesterase Inhibitor Discontinuation in Patients with Moderate to Severe Alzheimer’s Disease in a Long Term Care Setting
by: O'Regan, Jordana
Published: (2014)

Persistence of Cholinesterase Inhibitor Treatment in Dementia: Insights from a Naturalistic Study
by: Javier Olazarán, et al.
Published: (2013-03-01)

In vitro cholinesterase inhibitory activity of Areca catechu L.
by: M. Saeedi, et al.
Published: (2017-11-01)

Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer’s Disease: A 24-Week, Open-Label, Multicenter Study in Japan
by: Kengo Ueda, et al.
Published: (2019-08-01)

A retrospective study of cholinesterase inhibitors for Alzheimer's disease : the effect of cerebrovascular disease on patient outcomes and the impact of biases on the results.
by: Charbonneau, Claudie
Published: (2011)

A retrospective study of cholinesterase inhibitors for Alzheimer's disease : the effect of cerebrovascular disease on patient outcomes and the impact of biases on the results
by: Charbonneau, Claudie
Published: (2011)

Biological and Computational Studies for Dual Cholinesterases Inhibitory Effect of Zerumbone
by: Jayeong Hwang, et al.
Published: (2020-04-01)

Real-world evaluation of compliance and preference in Alzheimer’s disease treatment
by: Pai MC, et al.
Published: (2015-11-01)

Cholinesterase Inhibitors: A population-based assessment of resource utilization for patients with Alzheimer's dementia in Ontario
by: FONG, RAYMOND
Published: (2011)

Position Statement on Anti-Dementia Medication for Alzheimer’s Disease by Swiss Stakeholders
by: Giovanni B Frisoni, et al.
Published: (2021-08-01)

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
by: Deardorff WJ, et al.
Published: (2016-10-01)

RBC acetyl cholinesterase: A poor man’s early diagnostic biomarker for familial alzheimer’s and Parkinson’s disease dementia
by: Himmatrao Saluba Bawaskar, et al.
Published: (2015-01-01)

Chemical characterization of sulfated polysaccharides from Gracilaria gracilis and Ulva lactuca and their radical scavenging, metal chelating, and cholinesterase inhibitory activities
by: Tosin A. Olasehinde, et al.
Published: (2019-01-01)